Clinical Trials · NCT07717814
A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Amgen
- Enrollment
- 154
- Start date
- Nov 2024
- Locations
- 4 sites, United States
- Primary endpoint
- Maximum Observed Concentration (Cmax) of AMG 133